 Well, I want to echo what you've heard from folks already. Thank you all for coming here and advising us and giving us input about some key questions that we had that you've heard stated already. Let me point out NHGRI sort of took the lead in organizing this, but by no means is this really a workshop for us, as you're gonna see in some of the things I'm gonna show. This is really something that has become of great interest to NIH, but we were certainly willing, for reasons I will explain in a minute, to take the lead in trying to see this workshop become organized. I think, really, what Francis pointed out about this inventory of something on the order of 65,000 genomes to be sequenced or exomes to be sequenced in really the next short period of time. Of course, all of you are recognized that the reason this has all become possible, of course, is because this precipitous drop in the cost of DNA sequencing shown here, this iconic graph that we show frequently for the data that we've collected for our three largest sequencing centers, but I think it's emblematic of the state of the art with respect to the field of genome sequencing. We obviously have, as NHGRI's flagship effort in our extramural research program, our genome sequencing program, which we renewed last year, and while it has several new components of it that capitalize on new opportunities created by the reductions in the cost for genome sequencing, nonetheless, it still has in place as the major component of that program our large-scale genome sequencing centers at Baylor and at Broad Institute and at Washington University and shortly this evening you're gonna hear from Rick Wilson who directs the genome institute at Washington University. So we, of course, are thinking critically about how to capitalize on this prodigious amount of sequencing capacity just in these three centers alone, and institutes alone, but the fact of the matter is there's others that we support and there's, of course, others that we're very interested in as well, and just recognizing that capacity, we wanna deploy that capacity in the most effective way possible for our specific scientific objectives. That said, we're not the only ones, of course, who are thinking about this, and the reason for it, of course, is that these technologies are just resulting in a massive dissemination with respect to genome sequencing capabilities. It is not just NHGRI leading the way with respect to having the bulk of the sequencing funding that's going on, but rather the reason you see these tables around this room filled with individuals from other institutes is because, virtually all the NIH institutes are getting involved in this and using these same technologies for doing genome sequencing for their studies. If you actually wanna see some real data for that to put it in context and to also show you the trend, if you just do, in fiscal year 11, query the database of NIH grants, and if you use the key term genome sequencing, it's very interesting what it reveals, and especially when you can do a similar query over several years. So this is just some real data to indicate it, and blue is money that, and this is in dollars, millions of dollars, blue is genome institute, red is everybody else at NIH, all the other institutes. If you go back as recently as 2005, 2006, you can see that 68 or 70% or so of all grants given out key word genome sequencing would have been NHGRI grants, but now you can see, fast forward to last year, we have complete data, and in fact, the majority of the dollars being given out key word genome sequencing end up being outside of NHGRI, not even NHGRI. You can also follow this for grant numbers, and this is a little deceiving, because of course we give out a handful of very large grants, but nonetheless, the trend is pretty clear, that just in terms of total grant numbers were once upon a time we were hovering around a quarter of all the grants that would carry the key word genome sequence, you can see a considerable drop off in 2011, with a much larger number of grants given out by other institutes. This is actually a good thing, I don't wanna portray this as anything but a good thing, it's the dissemination of genomic capabilities across other NIH institutes. Of course we also have to realize that the same capacity that will end up being used to generate genome sequences, especially if human, is not gonna just be limited to the NIH. I would point out there's various other major players that are relevant to consider, and that we are certainly in contact with many of these. Certainly there's very large operations such as BGI, and certainly the Sanger Institute. I could have put here in this column, I don't know, 10 or 12 different ones, I just grabbed a few places I know that have some reasonable amount of sequencing capacity, but there's many others. And of course there's the private sector of which just a couple examples are shown here, who are developing considerable amounts of sequencing capacity as well. So in thinking about all the sequencing capacity, whether it be at NHGRIs, whether it be other NIH institutes, whether it be others in the international sphere or private sector, of course NHGRI is very interested in thinking about strategically how to deploy that for various purposes that is best encapsulated in a strategic plan that we published in February of last year, that I know many of the people sitting around this room have seen, this was again written and the strategic plan it was carried out by NHGRI, but in fact is very much on behalf of the whole field of genomics, and we recognize that many are gonna be pursuing the kind of objectives we lay out. This is sort of the iconic figure from that paper that portrays various domains of research activities going from more basic side to the more clinically applied side over different time intervals. I just wanna focus your attention because what's relevant to this meeting is this slice here. Really using genomic approaches in particular genome sequencing to help us understand the biology of disease. And I think it's what Eric Boerwinkel set up in some of the early points in his talk was the idea of really focusing our attention, especially on complex genetic diseases. And represented in this time interval where we're sitting is right in here, the next decade. And what we predicted in our strategic plan was that this was gonna be a very intense decade with respect to genomic achievements and pursuits and projects that were gonna be in particularly relevant to this middle domain. And of course that likely will continue even beyond 2020. So we are looking towards this next decade and beyond and we at NHGRI, but as Francis alludes to and certainly the case, it goes beyond NHGRI and all of NIH is really thinking towards the future. What are the right kinds of studies to design that would maximally capitalize on the kinds of sequencing capabilities that we have? I will tell you quite candidly the reason we have workshops like this is don't think for a minute we know precisely how to execute on this kind of a vision. We very much aim to learn. We are still students at this. These are very hard problems and NHGRI is continually trying to gain this kind of input and I think others at NIH certainly are as well. As Francis alluded to, we need to design the best and most effective studies for pursuing these goals, how to be most efficient, thinking about all the various options that one has. And so as Eric Warwinkle nicely laid out, there are many issues and there are many questions and they're just sort of shown here. He actually went through many of them bullet by bullet but we're gonna come back to these over and over again throughout this workshop to try to see as we are trying to learn what we can come to conclusions with respect to the trade-offs and the various issues that we need to try to address and to try to answer these fundamental questions that will help guide the design of some of these future studies. So once again, this is sort of a backdrop for why we are here and we're really eager to discuss, debate, strategize and hopefully try to answer these questions. So with that, I will stop and Terry, do I turn this over to someone or you're gonna take over? Or Eric's gonna take over, excellent. Thank you.